Search
for
Sort by
Research 271–300 of 982
- Novel small molecules downregulate CDK1 expression and inhibit Wnt/β-catenin signaling in cutaneous squamous cell carcinoma by targeting its distinct tumor-specific cellular landscape
- Molecular Signaling Pathways in Wound-Induced Hair-Follicle Neogenesis
- Dermal β-Catenin Is Required for Hedgehog-Driven Hair Follicle Neogenesis.
- Pyruvate Kinase M2 Promotes Hair Regeneration by Connecting Metabolic and Wnt//β-Catenin Signaling
- KY19382, a novel activator of Wnt/β-catenin signaling, promotes hair re-growth and hair follicle neogenesis
- CXXC5 Mediates DHT-Induced Androgenetic Alopecia via PGD2
- Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areata
- [Effect of 13-cis-retinoic acid on hair growth].
- Long-Term Efficacy of Ritlecitinib up to Month 24 From the ALLEGRO Phase 2b/3 and Long-Term Phase 3 Clinical Studies in Alopecia Areata
- Integrated Safety Analysis of Ritlecitinib for the Treatment of Alopecia Areata (AA) From the Phase 2 and Phase 3 ALLEGRO Clinical Trial Program
- Integrated Safety Analysis of Ritlecitinib in Adolescent Patients with Alopecia Areata from the Randomized, Placebo-Controlled ALLEGRO Phase 2b/3 and Ongoing Open-Label Phase 3 ALLEGRO-LT Studies
- Delphi Consensus Statement on Treatment of Severe Alopecia Areata in US Adults
- Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies
- Pediatric Clinical Trial Program in Progress: A Phase 3 Study and Long-term Extension Study to Evaluate the Efficacy and Safety of Ritlecitinib in Children 6 to <12 years of Age With Severe Alopecia Areata
- Baricitinib Provides Holistic Improvement in Scalp, Eyebrow and Eyelash Regrowth in Adolescents With Severe Alopecia Areata
- Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
- Alopecia areata incognita: A Hypothesis
- Prostate-Sparing Effects in Primates of the Potent Androgen 7α-Methyl-19-Nortestosterone: A Potential Alternative to Testosterone for Androgen Replacement and Male Contraception1
- Scalp, Skull, Orbit, and Maxilla Reconstruction and Hair Transplantation
- Review of the Use of Platelet-Rich Plasma in the Treatment of Alopecia
- Dupilumab: Friend or Foe to Alopecia Areata?
- Female hair loss
- Editor bids adieu
- Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer
- Large Scale Gene Expression Profiles of Regenerating Inner Ear Sensory Epithelia
- Neuronal plasticity of the “brain–skin connection”: stress-triggered up-regulation of neuropeptides in dorsal root ganglia and skin via nerve growth factor-dependent pathways
- Graft-versus-host disease
- Evaluating the Efficacy of Different Platelet-Rich Plasma Regimens for Management of Androgenetic Alopecia: A Single-Center, Blinded, Randomized Clinical Trial
- Comparison of clinical and laboratory characteristics of cases with polycystic ovarian syndrome based on Rotterdam’s criteria and women whose only clinical signs are oligo/anovulation or hirsutism
- Polycystic Ovarian Syndrome: Long-Term Health Consequences